{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:48:07Z","timestamp":1790480887033,"version":"4.1.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"36","license":[{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstact<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Metastatic gastric cancer patients with poor eastern cooperative oncology group performance status (PS) (\u22653) were lack of effective anti-tumor strategies. They always lived with poor PS, severe and multiple symptoms, and usually resulted in extremely limited survival time. Herein, we reported a patient diagnosed with gastric cancer metastasized to multiple bones, along with lymphangitis carcinomatosa in lungs, harboring Her-2 and c-MET amplification with poor PS, positively responded to combinational therapy with trastuzumab and crizotinib.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>The patient complained of persistent cough and fatigue for 2 months, otherwise, she denied smoking, alcohol history, or any other medical or family history.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>With the biopsy results from gastroscopy, as well as computer tomography for chest and abdomen, the patient was diagnosed as gastric adenocarcinoma, with metastasis on lungs, left adrenal gland, retroperitoneal lymph nodes, and multiple bones.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Because of the poor PS (PS\u200a=\u200a3), as well as Her-2 and c-MET amplification, the patient received combination treatment with trastuzumab and crizotinib as salvage strategy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After 2 months\u2019 exposure of trastuzumab and crizotinib, symptoms including persistent cough, and chest distress were alleviated significantly. Simultaneously, chest computer tomography showed significant dissipation of lymphangitis carcinomatosa, as well as apparent reduction of pleural effusion. No adverse reactions including nausea, vomiting, diarrhea, or hypertension was observed during the following 2 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>The present case suggested that combinational therapy with trastuzumab and crizotinib might be effective in metastatic gastric cancer patients harboring Her-2 and c-MET amplification, even with a poor PS. It was also implied that gene sequencing might be valuable, especially in patients with limited treatment strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000027017","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T13:03:01Z","timestamp":1631278981000},"page":"e27017","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Combination treatment with trastuzumab and crizotinib in metastatic gastric cancer harboring Her-2 amplification and c-MET amplification"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0148-3043","authenticated-orcid":false,"given":"Mingsheng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,9,10]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2217\/fon-2019-0728","article-title":"Risk factors and prognosis of bone metastases in newly diagnosed gastric cancer","volume":"16","author":"Liang","year":"2020","journal-title":"Future Oncol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2217\/fon-2019-0039","article-title":"Clinical analysis of bone metastasis of gastric cancer: incidence, clinicopathological features and survival","volume":"15","author":"Wen","year":"2019","journal-title":"Future Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jaad.2012.02.010","article-title":"Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0","volume":"67","author":"Chen","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","article-title":"HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target","volume":"19","author":"Gravalos","year":"2008","journal-title":"Ann Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/1535-7163.MCT-19-0455","article-title":"HER-family ligands promote acquired resistance to trastuzumab in gastric cancer","volume":"18","author":"Sampera","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1159\/000334055","article-title":"Positive response to trastuzumab in a case of HER2-overexpressing metastatic gastric cancer that presented as severe thrombocytopenia","volume":"34","author":"Choi","year":"2011","journal-title":"Onkologie"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/JTO.0b013e31821528d3","article-title":"Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification","volume":"6","author":"Ou","year":"2011","journal-title":"J Thorac Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/bjc.2014.61","article-title":"HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma","volume":"110","author":"Liu","year":"2014","journal-title":"Br J Cancer"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s10120-015-0545-5","article-title":"MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer","volume":"19","author":"Yang","year":"2016","journal-title":"Gastric Cancer"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.3934\/mbe.2019296","article-title":"Gastric cancer patient with c-MET amplification treated with crizotinib after failed multi-line treatment: a case report and literature review","volume":"16","author":"Hou","year":"2019","journal-title":"Math Biosci Eng"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.annonc.2019.11.016","article-title":"Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification","volume":"31","author":"Mazzotta","year":"2020","journal-title":"Ann Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:37:05Z","timestamp":1746333425000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027017"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,9,10]]},"references-count":15,"journal-issue":{"issue":"36","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000027017","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,10]]},"assertion":[{"value":"2021-03-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}